@ohpkease777 - Mayo Clinic has some information that may help answer your question.
"Currently, there is no definitive treatment of post-COVID syndrome. The recommendations presented here are based on expert opinion and will likely evolve as more evidence emerges. Although neuroinflammation is a proposed mechanism, there is insufficient evidence for recommending anti-inflammatory therapeutics for these patients. Whereas clinical experience exists for similar syndromes, such as fibromyalgia, ME/CFS, and POTS, there are only limited evidence-based treatment options for these conditions. Therefore, the mainstay treatments of PCC are symptom management, rehabilitation, reassurance and support, and therapies to reduce sympathetic hyperactivity."
-- Post-COVID Conditions: https://www.mayoclinicproceedings.org/article/S0025-6196(23)00176-3/fulltext

-- Mayo Clinic expert shares 5 early care tips for people with long COVID:
https://newsnetwork.mayoclinic.org/discussion/mayo-clinic-expert-shares-5-early-care-tips-for-people-with-long-covid/

@ohpkease777 there are many research studies and clinical trials trying to get at the heart of this, and to see if the “persistent viral reservoirs” are even responsible for LC symptoms…

Off the top of my head, they are looking at anti-virals (Paxlovid was a bust - UCSF), JAK-STAT inhibitors, monoclonal antibodies, and “blood-derived cell therapies” like RegeneCyte, which I had never heard of, and was quite interesting.

However, as John mentioned, there are no definitive interventions that have been proven to reduce spike protein or viral fragment load in patients, yet.